Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development

Cristal S. Yee, Jennifer O. Manilay, Jiun C. Chang, Nicholas R. Hum, Deepa K. Murugesh, Jamila Bajwa, Melanie E. Mendez, Aris E. Economides, Daniel J. Horan, Alexander Robling, Gabriela G. Loots

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Sclerostin (Sost) is a negative regulator of bone formation and blocking its function via antibodies has shown great therapeutic promise by increasing both bone mass in humans and animal models. Sclerostin deletion in Sost KO mice (Sost−/−) causes high bone mass (HBM) similar to sclerosteosis patients. Sost−/− mice have been shown to display an up to 300% increase in bone volume/total volume (BV/TV), relative to age-matched controls. It has been postulated that the main source of skeletal sclerostin is the osteocyte. To understand the cell-type specific contributions to the HBM phenotype described in Sost−/− mice, as well as to address the endocrine and paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-function (SostiCOIN/iCOIN) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre; targets osteoprogenitors and their progeny); (2) midstage osteoblasts and their progenitors (Col1-Cre); (3) mature osteocytes (Dmp1-Cre); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre). All conditional alleles resulted in significant increases in bone mass in trabecular bone in both the femur and lumbar vertebrae, but only Prx1-Cre deletion fully recapitulated the amplitude of the HBM phenotype in the appendicular skeleton and the B-cell defect described in the global KO. Despite WT expression of Sost in the axial skeleton of Prx1-Cre deleted mice, these mice also had a significant increase in bone mass in the vertebrae, but the sclerostin released in circulation by the axial skeleton did not affect bone parameters in the appendicular skeleton. Also, both Col1 and Dmp1 deletion resulted in a similar 80% significant increase in trabecular bone mass, but only Col1 and Prx1 deletion resulted in a significant increase in cortical thickness. We conclude that several cell types within the Prx1-osteoprogenitor-derived lineages contribute significant amounts of sclerostin protein to the paracrine pool of Sost in bone.

Original languageEnglish (US)
Pages (from-to)1748-1759
Number of pages12
JournalJournal of Bone and Mineral Research
Volume33
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

B-Lymphocytes
Bone and Bones
Skeleton
Osteocytes
Lumbar Vertebrae
Mesoderm
Chondrocytes
Osteoblasts
Osteogenesis
Femur
Spine
Extremities
Animal Models
Alleles
Phenotype
Antibodies
Proteins

Keywords

  • CHONDROCYTE
  • MSC
  • OSTEOBLAST
  • OSTEOCYTE
  • SCLEROSTIN
  • WnT
  • WnT SIGNALING

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Orthopedics and Sports Medicine

Cite this

Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development. / Yee, Cristal S.; Manilay, Jennifer O.; Chang, Jiun C.; Hum, Nicholas R.; Murugesh, Deepa K.; Bajwa, Jamila; Mendez, Melanie E.; Economides, Aris E.; Horan, Daniel J.; Robling, Alexander; Loots, Gabriela G.

In: Journal of Bone and Mineral Research, Vol. 33, No. 10, 01.10.2018, p. 1748-1759.

Research output: Contribution to journalArticle

Yee, CS, Manilay, JO, Chang, JC, Hum, NR, Murugesh, DK, Bajwa, J, Mendez, ME, Economides, AE, Horan, DJ, Robling, A & Loots, GG 2018, 'Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development', Journal of Bone and Mineral Research, vol. 33, no. 10, pp. 1748-1759. https://doi.org/10.1002/jbmr.3467
Yee, Cristal S. ; Manilay, Jennifer O. ; Chang, Jiun C. ; Hum, Nicholas R. ; Murugesh, Deepa K. ; Bajwa, Jamila ; Mendez, Melanie E. ; Economides, Aris E. ; Horan, Daniel J. ; Robling, Alexander ; Loots, Gabriela G. / Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development. In: Journal of Bone and Mineral Research. 2018 ; Vol. 33, No. 10. pp. 1748-1759.
@article{2cc7c65fb1294bb99db349c334aeb994,
title = "Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development",
abstract = "Sclerostin (Sost) is a negative regulator of bone formation and blocking its function via antibodies has shown great therapeutic promise by increasing both bone mass in humans and animal models. Sclerostin deletion in Sost KO mice (Sost−/−) causes high bone mass (HBM) similar to sclerosteosis patients. Sost−/− mice have been shown to display an up to 300{\%} increase in bone volume/total volume (BV/TV), relative to age-matched controls. It has been postulated that the main source of skeletal sclerostin is the osteocyte. To understand the cell-type specific contributions to the HBM phenotype described in Sost−/− mice, as well as to address the endocrine and paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-function (SostiCOIN/iCOIN) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre; targets osteoprogenitors and their progeny); (2) midstage osteoblasts and their progenitors (Col1-Cre); (3) mature osteocytes (Dmp1-Cre); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre). All conditional alleles resulted in significant increases in bone mass in trabecular bone in both the femur and lumbar vertebrae, but only Prx1-Cre deletion fully recapitulated the amplitude of the HBM phenotype in the appendicular skeleton and the B-cell defect described in the global KO. Despite WT expression of Sost in the axial skeleton of Prx1-Cre deleted mice, these mice also had a significant increase in bone mass in the vertebrae, but the sclerostin released in circulation by the axial skeleton did not affect bone parameters in the appendicular skeleton. Also, both Col1 and Dmp1 deletion resulted in a similar 80{\%} significant increase in trabecular bone mass, but only Col1 and Prx1 deletion resulted in a significant increase in cortical thickness. We conclude that several cell types within the Prx1-osteoprogenitor-derived lineages contribute significant amounts of sclerostin protein to the paracrine pool of Sost in bone.",
keywords = "CHONDROCYTE, MSC, OSTEOBLAST, OSTEOCYTE, SCLEROSTIN, WnT, WnT SIGNALING",
author = "Yee, {Cristal S.} and Manilay, {Jennifer O.} and Chang, {Jiun C.} and Hum, {Nicholas R.} and Murugesh, {Deepa K.} and Jamila Bajwa and Mendez, {Melanie E.} and Economides, {Aris E.} and Horan, {Daniel J.} and Alexander Robling and Loots, {Gabriela G.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1002/jbmr.3467",
language = "English (US)",
volume = "33",
pages = "1748--1759",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Conditional Deletion of Sost in MSC-Derived Lineages Identifies Specific Cell-Type Contributions to Bone Mass and B-Cell Development

AU - Yee, Cristal S.

AU - Manilay, Jennifer O.

AU - Chang, Jiun C.

AU - Hum, Nicholas R.

AU - Murugesh, Deepa K.

AU - Bajwa, Jamila

AU - Mendez, Melanie E.

AU - Economides, Aris E.

AU - Horan, Daniel J.

AU - Robling, Alexander

AU - Loots, Gabriela G.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Sclerostin (Sost) is a negative regulator of bone formation and blocking its function via antibodies has shown great therapeutic promise by increasing both bone mass in humans and animal models. Sclerostin deletion in Sost KO mice (Sost−/−) causes high bone mass (HBM) similar to sclerosteosis patients. Sost−/− mice have been shown to display an up to 300% increase in bone volume/total volume (BV/TV), relative to age-matched controls. It has been postulated that the main source of skeletal sclerostin is the osteocyte. To understand the cell-type specific contributions to the HBM phenotype described in Sost−/− mice, as well as to address the endocrine and paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-function (SostiCOIN/iCOIN) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre; targets osteoprogenitors and their progeny); (2) midstage osteoblasts and their progenitors (Col1-Cre); (3) mature osteocytes (Dmp1-Cre); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre). All conditional alleles resulted in significant increases in bone mass in trabecular bone in both the femur and lumbar vertebrae, but only Prx1-Cre deletion fully recapitulated the amplitude of the HBM phenotype in the appendicular skeleton and the B-cell defect described in the global KO. Despite WT expression of Sost in the axial skeleton of Prx1-Cre deleted mice, these mice also had a significant increase in bone mass in the vertebrae, but the sclerostin released in circulation by the axial skeleton did not affect bone parameters in the appendicular skeleton. Also, both Col1 and Dmp1 deletion resulted in a similar 80% significant increase in trabecular bone mass, but only Col1 and Prx1 deletion resulted in a significant increase in cortical thickness. We conclude that several cell types within the Prx1-osteoprogenitor-derived lineages contribute significant amounts of sclerostin protein to the paracrine pool of Sost in bone.

AB - Sclerostin (Sost) is a negative regulator of bone formation and blocking its function via antibodies has shown great therapeutic promise by increasing both bone mass in humans and animal models. Sclerostin deletion in Sost KO mice (Sost−/−) causes high bone mass (HBM) similar to sclerosteosis patients. Sost−/− mice have been shown to display an up to 300% increase in bone volume/total volume (BV/TV), relative to age-matched controls. It has been postulated that the main source of skeletal sclerostin is the osteocyte. To understand the cell-type specific contributions to the HBM phenotype described in Sost−/− mice, as well as to address the endocrine and paracrine mode of action of sclerostin, we examined the skeletal phenotypes of conditional Sost loss-of-function (SostiCOIN/iCOIN) mice with specific deletions in (1) the limb mesenchyme (Prx1-Cre; targets osteoprogenitors and their progeny); (2) midstage osteoblasts and their progenitors (Col1-Cre); (3) mature osteocytes (Dmp1-Cre); and (4) hypertrophic chondrocytes and their progenitors (ColX-Cre). All conditional alleles resulted in significant increases in bone mass in trabecular bone in both the femur and lumbar vertebrae, but only Prx1-Cre deletion fully recapitulated the amplitude of the HBM phenotype in the appendicular skeleton and the B-cell defect described in the global KO. Despite WT expression of Sost in the axial skeleton of Prx1-Cre deleted mice, these mice also had a significant increase in bone mass in the vertebrae, but the sclerostin released in circulation by the axial skeleton did not affect bone parameters in the appendicular skeleton. Also, both Col1 and Dmp1 deletion resulted in a similar 80% significant increase in trabecular bone mass, but only Col1 and Prx1 deletion resulted in a significant increase in cortical thickness. We conclude that several cell types within the Prx1-osteoprogenitor-derived lineages contribute significant amounts of sclerostin protein to the paracrine pool of Sost in bone.

KW - CHONDROCYTE

KW - MSC

KW - OSTEOBLAST

KW - OSTEOCYTE

KW - SCLEROSTIN

KW - WnT

KW - WnT SIGNALING

UR - http://www.scopus.com/inward/record.url?scp=85052899502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052899502&partnerID=8YFLogxK

U2 - 10.1002/jbmr.3467

DO - 10.1002/jbmr.3467

M3 - Article

C2 - 29750826

AN - SCOPUS:85052899502

VL - 33

SP - 1748

EP - 1759

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 10

ER -